Clinical efficacy and safety observation of bevacizumab combined with docetaxel in treatment of advanced cervix cancer
10.7501/j.issn.1674-6376.2017.01.019
- VernacularTitle:贝伐单抗联合多西他赛治疗晚期宫颈癌的临床疗效及安全性观察
- Author:
Weixia ZHANG
;
Ting YANG
;
Juanni LIU
;
Fenxia LI
;
Lei CHEN
- Keywords:
advanced cervix cancer;
bevacizumab;
docetaxel;
curative effect;
safety
- From:
Drug Evaluation Research
2017;40(1):100-103
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the clinical efficacy and safety of bevacizumab combined with docetaxel in treatment of advanced cervix cancer.Methods Seventy-five patients with advanced cervix cancer accepted in our hospital from April 2011 to April 2016 were selected and divided into observation group with 43 cases and control group with 32 cases according to different treatment methods.Patients in control group were given docetaxel,and patients in observation group were combined with bevacizumab on the basis of control group.The clinical efficacy,adverse reactions,life quality and pharmacoeconomics of two groups were observed and compared.Results The total efficacy and clinical control rate of observation group were all higher than control group with statistically significance (P ＜ 0.05).The adverse reaction rate of two groups had no difference.Total efficacy of life quality improvement was 83.72％,which was obviously higher than control group 62.50％ with statistically significance (P ＜ 0.05).The average cost of observation group was (83 ± 10) thousands,of control group was (18± 6) thousands.The cost of observation group was obviously higher than control group with statistically significance (P ＜ 0.05).Conclusion Using bevacizumab combined with docetaxel in treatment of advanced cervix cancer has better effect clinical but costs much than docetaxel.We should set on treatment according to patients' own situation.
